PJSC Kraspharma has launched a new polypeptide antibiotic, Ingastin, in the form of a powder for preparing a solution for intravenous administration and inhalation.
25.02.2025
PJSC Kraspharma has launched a new polypeptide antibiotic, Ingastin, in the form of a powder for preparing a solution for intravenous administration and inhalation.
Polymyxins, particularly colistimethate, remain the only therapeutic option for treating life-threatening infections caused by Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae (e.g., Klebsiella spp.). Colistimethate is distinguished by its unique mechanism of action and lack of cross-resistance with other antibiotic classes, delivering a strong antimicrobial effect against multidrug-resistant Gram-negative nosocomial pathogens.
Susceptibility rates to colistimethate remain exceptionally high among hospital-acquired strains:
Ingastin, a new product by PJSC Kraspharma, acts as a last-line "antidote," offering critically ill patients a real chance of recovery—even when treatment options appear exhausted. For intravenous use, Ingastin has a broad range of indications, primarily infections caused by aerobic Gram-negative microorganisms sensitive to colistimethate sodium, in both adults and children with limited antibiotic treatment options.
Additionally, since P. aeruginosa is the most common pathogen in chronic infections in cystic fibrosis patients, inhaled colistimethate is recognized as a standard of care for its eradication. Therefore, Ingastin, when used as part of combination therapy for cystic fibrosis, contributes to bacterial clearance, improved lung function, and earlier remission.
View in catalog
Susceptibility rates to colistimethate remain exceptionally high among hospital-acquired strains:
- P. aeruginosa – 99.48%
- A. baumannii – 99.57%
- E. coli – 98.38%
- K. pneumoniae – 94.41%
Ingastin, a new product by PJSC Kraspharma, acts as a last-line "antidote," offering critically ill patients a real chance of recovery—even when treatment options appear exhausted. For intravenous use, Ingastin has a broad range of indications, primarily infections caused by aerobic Gram-negative microorganisms sensitive to colistimethate sodium, in both adults and children with limited antibiotic treatment options.
Additionally, since P. aeruginosa is the most common pathogen in chronic infections in cystic fibrosis patients, inhaled colistimethate is recognized as a standard of care for its eradication. Therefore, Ingastin, when used as part of combination therapy for cystic fibrosis, contributes to bacterial clearance, improved lung function, and earlier remission.
View in catalog
